Patients & Community
Every person’s experience with Parkinson's is different, and we believe their treatment should be, too. With a deep commitment to innovation, collaboration, and better outcomes, we’re working to change what’s possible for patients and families everywhere.
The NEULARK Clinical Trial
We are actively conducting the NEULARK clinical trial to evaluate the safety and efficacy of our LRRK2 inhibitor, NEU-411, in people with early stage Parkinson’s disease.
The NEULARK study (NCT06680830) is evaluating the safety and efficacy of NEU-411 in newly diagnosed, dopamine naïve individuals with LRRK2-driven Parkinson’s disease. This trial aims to investigate whether NEU-411 can potentially slow disease progression and will utilize the first precision medicine patient selection approach in Parkinson’s disease to identify people with LRRK2-driven disease who we believe are most likely to benefit from NEU-411.
Clinical Trial Inquiries
For inquiries related to our clinical trials, please contact us at clinicaltrials@neuron23.com.
We welcome questions from patients, caregivers, and healthcare professionals interested in our research initiatives.
We welcome questions from patients, caregivers, and healthcare professionals interested in our research initiatives.
Our Commitment to Patients
We are deeply committed to improving the lives of people facing Parkinson’s disease. We understand that each individual is unique, which is why we prioritize a personalized medicine approach. By leveraging advanced scientific methodologies, including machine learning and genetic insights, we are developing a targeted therapy that aims to address the specific needs of a subset of the diverse PD population with significant unmet medical need. Our focus is on transforming the future of treatment for PD through innovation, collaboration, and dedication to enhancing patient outcomes.